cilostazol has been researched along with Cardiovascular Diseases in 30 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the impact of polymorphisms of metabolic enzymes on plasma concentrations of cilostazol and its metabolites, and the influence of the plasma concentrations and polymorphisms on the cardiovascular side effects in 30 patients with cerebral infarction." | 8.02 | Impact of Cilostazol Pharmacokinetics on the Development of Cardiovascular Side Effects in Patients with Cerebral Infarction. ( Asahara, Y; Kagawa, Y; Kaneshiro, Y; Maeda, T; Murata, K; Urano, Y; Yamagata, K; Yamauchi, S; Yokoyama, T, 2021) |
| " Here, the effects of the phosphodiesterase (PDE) inhibitors vardenafil and cilostazol were examined against rheumatoid arthritis (RA)/diabetes mellitus (DM)-co-morbidity-induced endothelial dysfunction and vascular reactivity defects." | 7.91 | Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity. ( Abo-Saif, AA; El-Daly, ME; Messiha, BAS; Wahba, MGF, 2019) |
| "In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke." | 5.27 | Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018) |
| "Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD)." | 5.13 | Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). ( Brass, EP; Hiatt, WR; Money, SR, 2008) |
| "This study investigated the impact of polymorphisms of metabolic enzymes on plasma concentrations of cilostazol and its metabolites, and the influence of the plasma concentrations and polymorphisms on the cardiovascular side effects in 30 patients with cerebral infarction." | 4.02 | Impact of Cilostazol Pharmacokinetics on the Development of Cardiovascular Side Effects in Patients with Cerebral Infarction. ( Asahara, Y; Kagawa, Y; Kaneshiro, Y; Maeda, T; Murata, K; Urano, Y; Yamagata, K; Yamauchi, S; Yokoyama, T, 2021) |
| " Here, the effects of the phosphodiesterase (PDE) inhibitors vardenafil and cilostazol were examined against rheumatoid arthritis (RA)/diabetes mellitus (DM)-co-morbidity-induced endothelial dysfunction and vascular reactivity defects." | 3.91 | Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity. ( Abo-Saif, AA; El-Daly, ME; Messiha, BAS; Wahba, MGF, 2019) |
| " The circulating SP-D level was affected by sex, diabetes mellitus, and cilostazol prescription." | 3.88 | Circulating Surfactant Protein-D Is Associated With Clinical Outcomes in Peripheral Artery Disease Patients Following Endovascular Therapy. ( Arimoto, T; Kubota, I; Miyamoto, T; Nishiyama, S; Otaki, Y; Shishido, T; Sugai, T; Takahashi, H; Watanabe, M; Watanabe, T; Yamanaka, T; Yokoyama, M, 2018) |
| "The purpose of the study is to evaluate the effectiveness of risk minimization measures-labeling changes and communication to health care professionals-recommended by the European Medicines Agency for use of cilostazol for the treatment of intermittent claudication in Europe." | 3.88 | Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. ( Arana, A; Bui, C; Calingaert, B; Castellsague, J; Giner-Soriano, M; Gonzalez-Rubio, F; Laguna, C; Linder, M; Perez-Gutthann, S; Poblador-Plou, B; Prados-Torres, A; Roso-Llorach, A; Scholle, O, 2018) |
| "In this collaborative European study, most cilostazol users were elderly patients with a high prevalence of cardiovascular diseases and other comorbidity and concurrent use of interacting drugs, indicating that this is a vulnerable population at high risk of complications, especially cardiovascular events." | 3.85 | Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. ( Arana, A; Blenk, T; Bui, C; Calingaert, B; Castellsague, J; Citarella, A; Garbe, E; Giner-Soriano, M; Gonzalez-Rubio, F; Linder, M; Perez-Gutthann, S; Poblador-Plou, B; Prados-Torres, A; Roso-Llorach, A; Scholle, O; Varas-Lorenzo, C, 2017) |
| "One possible cause of stent thrombosis is an insufficient effect of clopidogrel." | 3.77 | Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. ( Behr, T; Behr, W; Kuch, B; von Scheidt, W, 2011) |
| "We randomly assigned 116 patients with type 2 diabetes and cardiovascular risk factors but no evident cardiovascular disease to receive aspirin at a dose of 100 mg or cilostazol at a dose of 200 mg daily for 14 days." | 3.11 | Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease. ( Hong, S; Lee, WJ; Park, CY, 2022) |
| " Decreased trend of negative outcomes could be observed in patients with double dosage of clopidogrel, but the difference was not significant." | 2.87 | Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. ( Chen, J; Gao, R; Huang, X; Qiao, S; Tang, YD; Wang, W; Wu, Y; Xu, B; Yan, H; Yang, M; Yang, Y; Zhang, K, 2018) |
| "Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival." | 2.78 | Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013) |
| "In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation." | 2.49 | Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. ( Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013) |
| " This systematic review assesses the efficacy and safety of adjunctive cilostazol to DAT in combination with DAT on reducing clinical adverse events." | 2.49 | Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. ( Ding, XL; Gao, J; Jiang, B; Miao, LY; Xie, C; Zhang, H; Zhang, JJ; Zhang, LL, 2013) |
| "Cilostazol is a potent type III phosphodiesterase inhibitor with pharmacological effects that include vasodilatation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth." | 2.44 | Cilostazol in the management of vascular disease. ( Dalainas, I, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 8 (26.67) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yokoyama, T | 1 |
| Yamauchi, S | 1 |
| Yamagata, K | 1 |
| Kaneshiro, Y | 1 |
| Urano, Y | 1 |
| Murata, K | 1 |
| Maeda, T | 1 |
| Asahara, Y | 1 |
| Kagawa, Y | 1 |
| Hong, S | 1 |
| Lee, WJ | 1 |
| Park, CY | 1 |
| Tang, YD | 1 |
| Wang, W | 1 |
| Yang, M | 1 |
| Zhang, K | 1 |
| Chen, J | 1 |
| Qiao, S | 1 |
| Yan, H | 1 |
| Wu, Y | 1 |
| Huang, X | 1 |
| Xu, B | 1 |
| Gao, R | 1 |
| Yang, Y | 1 |
| Otaki, Y | 1 |
| Watanabe, T | 1 |
| Takahashi, H | 1 |
| Sugai, T | 1 |
| Yokoyama, M | 1 |
| Nishiyama, S | 1 |
| Arimoto, T | 1 |
| Shishido, T | 1 |
| Miyamoto, T | 1 |
| Yamanaka, T | 1 |
| Kubota, I | 1 |
| Watanabe, M | 1 |
| Kim, BJ | 1 |
| Lee, EJ | 1 |
| Kwon, SU | 1 |
| Park, JH | 1 |
| Kim, YJ | 1 |
| Hong, KS | 1 |
| Wong, LKS | 1 |
| Yu, S | 1 |
| Hwang, YH | 1 |
| Lee, JS | 1 |
| Lee, J | 1 |
| Rha, JH | 1 |
| Heo, SH | 1 |
| Ahn, SH | 1 |
| Seo, WK | 1 |
| Park, JM | 1 |
| Lee, JH | 1 |
| Kwon, JH | 1 |
| Sohn, SI | 1 |
| Jung, JM | 2 |
| Navarro, JC | 1 |
| Kang, DW | 1 |
| Castellsague, J | 2 |
| Poblador-Plou, B | 2 |
| Giner-Soriano, M | 2 |
| Linder, M | 2 |
| Scholle, O | 2 |
| Calingaert, B | 2 |
| Bui, C | 2 |
| Arana, A | 2 |
| Laguna, C | 1 |
| Gonzalez-Rubio, F | 2 |
| Roso-Llorach, A | 2 |
| Prados-Torres, A | 2 |
| Perez-Gutthann, S | 2 |
| Wahba, MGF | 1 |
| Messiha, BAS | 1 |
| El-Daly, ME | 1 |
| Abo-Saif, AA | 1 |
| Iida, O | 1 |
| Yokoi, H | 1 |
| Soga, Y | 1 |
| Inoue, N | 1 |
| Suzuki, K | 1 |
| Yokoi, Y | 1 |
| Kawasaki, D | 1 |
| Zen, K | 1 |
| Urasawa, K | 1 |
| Shintani, Y | 1 |
| Miyamoto, A | 1 |
| Hirano, K | 1 |
| Miyashita, Y | 1 |
| Tsuchiya, T | 1 |
| Shinozaki, N | 1 |
| Nakamura, M | 1 |
| Isshiki, T | 1 |
| Hamasaki, T | 1 |
| Nanto, S | 1 |
| Huh, JH | 1 |
| Seok, H | 1 |
| Lee, BW | 1 |
| Kang, ES | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Park, Y | 1 |
| Tantry, US | 1 |
| Kim, K | 1 |
| Koh, JS | 1 |
| Park, JR | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Kim, S | 1 |
| Gurbel, PA | 1 |
| Jeong, YH | 1 |
| Chao, TH | 1 |
| Chen, IC | 1 |
| Lee, CH | 1 |
| Chen, JY | 1 |
| Tsai, WC | 1 |
| Li, YH | 1 |
| Tseng, SY | 1 |
| Tsai, LM | 1 |
| Tseng, WK | 1 |
| Varas-Lorenzo, C | 1 |
| Citarella, A | 1 |
| Blenk, T | 1 |
| Garbe, E | 1 |
| Grove, EL | 1 |
| Kristensen, SD | 1 |
| Shigematsu, H | 1 |
| Nishibe, T | 1 |
| Obitsu, Y | 1 |
| Matsuzaki, K | 1 |
| Ishida, A | 1 |
| Miyata, T | 1 |
| Shindo, S | 1 |
| Hida, K | 1 |
| Ohta, T | 1 |
| Ando, M | 1 |
| Kawasaki, T | 1 |
| Yasugi, T | 1 |
| Matsumoto, T | 1 |
| Olin, JW | 1 |
| Sealove, BA | 1 |
| Rhee, SY | 1 |
| Kim, YS | 1 |
| Chon, S | 1 |
| Oh, S | 1 |
| Woo, JT | 1 |
| Kim, SW | 1 |
| Kim, JW | 1 |
| Park, KW | 1 |
| Park, JJ | 1 |
| Lee, SP | 1 |
| Oh, IY | 1 |
| Suh, JW | 1 |
| Yang, HM | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Cho, YS | 1 |
| Koo, BK | 2 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Kim, HS | 1 |
| Behr, T | 1 |
| Kuch, B | 1 |
| Behr, W | 1 |
| von Scheidt, W | 1 |
| Takagi, H | 1 |
| Umemoto, T | 1 |
| Sakurai, R | 1 |
| Kaneda, H | 1 |
| Bonneau, HN | 1 |
| Nagai, R | 1 |
| Ding, XL | 1 |
| Xie, C | 1 |
| Jiang, B | 1 |
| Gao, J | 1 |
| Zhang, LL | 1 |
| Zhang, H | 1 |
| Zhang, JJ | 1 |
| Miao, LY | 1 |
| Brass, EP | 2 |
| Lewis, RJ | 1 |
| Lipicky, R | 1 |
| Murphy, J | 1 |
| Hiatt, WR | 3 |
| Dalainas, I | 1 |
| Meadows, TA | 1 |
| Bhatt, DL | 1 |
| Agrawal, NK | 1 |
| Maiti, R | 1 |
| Dash, D | 1 |
| Pandey, BL | 1 |
| Mocanu, MM | 1 |
| Shakkottai, P | 1 |
| Yellon, DM | 1 |
| Money, SR | 1 |
| Saniabadi, AR | 1 |
| Takeich, S | 1 |
| Yukawa, N | 1 |
| Nakajima, Y | 1 |
| Umemura, K | 1 |
| Nakashima, M | 1 |
| Regensteiner, JG | 1 |
| Numano, F | 1 |
| Kishi, Y | 1 |
| Ashikaga, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients[NCT02933788] | Phase 4 | 116 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.[NCT01779401] | 1,078 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756] | Phase 4 | 200 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Effect of Cilostazol, a Phosphodiesterase 3 Inhibitor, on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes[NCT03248401] | Phase 4 | 50 participants (Actual) | Interventional | 2016-09-26 | Completed | ||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
10 reviews available for cilostazol and Cardiovascular Diseases
| Article | Year |
|---|---|
Update on oral antiplatelet therapy: principles, problems and promises.
Topics: Adenosine; Administration, Oral; Cardiovascular Diseases; Cilostazol; Coronary Artery Disease; Coron | 2009 |
Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cilostazol; Humans; Prospective Studies; Ra | 2011 |
Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combin | 2013 |
Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2013 |
Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.
Topics: Algorithms; Cardiovascular Agents; Cardiovascular Diseases; Cilostazol; Humans; Risk Assessment; Tet | 2006 |
Cilostazol in the management of vascular disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; | 2007 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
The power of drug co-administration: smaller doses better outcomes.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cilostazol; Dose-Response Relationship, Drug; Drug T | 2007 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
Clinical studies of phosphodiesterase inhibitors for cardiovascular disease.
Topics: Adult; Aged; Animals; Cardiovascular Diseases; Cilostazol; Cyclic AMP; Cyclic GMP; Female; Humans; M | 1992 |
9 trials available for cilostazol and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Cilostazol; Clopidogrel; Cytochrome P-450 CY | 2018 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh | 2018 |
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Aspirin; Cardiovascular Diseases; Cilostazol; Constric | 2013 |
Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.
Topics: Cardiovascular Diseases; Cilostazol; Clopidogrel; Female; Follow-Up Studies; Humans; Lansoprazole; M | 2014 |
Cilostazol Enhances Mobilization of Circulating Endothelial Progenitor Cells and Improves Endothelium-Dependent Function in Patients at High Risk of Cardiovascular Disease.
Topics: Aged; Antigens, CD34; Cardiovascular Diseases; Cell Movement; Cilostazol; Double-Blind Method; Endot | 2016 |
Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Cilostazol; Clopidog | 2011 |
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood Sedimentation; C-Reactive Protein; Cardiovascular Dise | 2007 |
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Topics: Aged; Cardiovascular Diseases; Cilostazol; Double-Blind Method; Female; Hemorrhage; Humans; Intermit | 2008 |
11 other studies available for cilostazol and Cardiovascular Diseases
| Article | Year |
|---|---|
Impact of Cilostazol Pharmacokinetics on the Development of Cardiovascular Side Effects in Patients with Cerebral Infarction.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Diseases; Cerebral Infarction; Cilostazol; C | 2021 |
Circulating Surfactant Protein-D Is Associated With Clinical Outcomes in Peripheral Artery Disease Patients Following Endovascular Therapy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cilostazol; Diabetes Mellitus; Endovascular Proced | 2018 |
Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany.
Topics: Aged; Cardiovascular Diseases; Cilostazol; Databases, Factual; Dose-Response Relationship, Drug; Dru | 2018 |
Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cardiovascular Diseases; Cilostazol; Comorb | 2019 |
Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event.
Topics: Aged; Cardiovascular Diseases; Carotid Arteries; Carotid Intima-Media Thickness; Cilostazol; Diabete | 2014 |
Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany.
Topics: Aged; Cardiovascular Diseases; Cilostazol; Databases, Factual; Drug Labeling; Drug Utilization; Fema | 2017 |
Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular | 2010 |
Peripheral artery disease: current insight into the disease and its diagnosis and management.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Cilostazol; Diagnosis, Differential; Disease Progress | 2010 |
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty | 2011 |
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascula | 2011 |
Apo E4/3-rich remnant lipoproteins and platelet aggregation: a case report.
Topics: 2-Chloroadenosine; Adenosine Diphosphate; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; A | 1998 |